Chronic Myelomonocytic Leukemia Clinical Trial
Official title:
A Phase I And Pharmacological Trial Of 17-Allylamino -17-demethoxygeldanamycin (17-AAG) And Cytarabine In Refractory Leukemia And Myelodysplastic Syndrome
This phase I trial is studying the side effects and best dose of tanespimycin when given with cytarabine in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes. Drugs used in chemotherapy, such as tanespimycin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Tanespimycin may also help cytarabine kill more cancer cells by making cancer cells more sensitive to the drug. Giving tanespimycin together with cytarabine may kill more cancer cells.
Status | Completed |
Enrollment | 42 |
Est. completion date | |
Est. primary completion date | May 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosis of 1 of the following: - Acute myeloid leukemia, except acute promyelocytic leukemia (M3 disease), meeting 1 of the following criteria: - Failed to achieve complete remission (CR) after initial induction therapy regimen* - First relapse within 1 year of initial CR - Failed re-induction therapy at first or second relapse - Second or third relapse after completing = 3 different induction therapy regimens - Antecedent hematologic disorder (myelodysplastic syndromes [MDS], chronic myeloproliferative disease, or chronic myelomonocytic leukemia [CMML]) - Received prior chemotherapy for a non-hematologic malignancy - High-risk cytogenetic abnormalities (abnormalities of chromosome 5, 7, 8, or 11 OR = 3 karyotypic abnormalities) - Acute lymphoblastic leukemia, meeting 1 of the following criteria: - Failed to achieve CR after initial induction therapy regimen - First relapse within 1 year of initial CR - Failed re-induction therapy at first or second relapse - Second or third relapse after completing = 3 different induction therapy regimens - Chronic myelogenous leukemia, meeting the following criteria: - Accelerated OR blast phase (> 10% increase in the blast percentage in bone marrow) - Failed prior imatinib mesylate - No more than 1 prior chemotherapy regimen in addition to imatinib mesylate - CMML, meeting the following criteria: - More than 10% increase in blast percentage AND organ infiltration OR impending marrow failure as evidenced by cytopenia - No t(5;12) by cytogenetics (unless failed prior trial of imatinib mesylate) - High-grade MDS, defined as > 10% blasts on marrow cellularity (refractory anemia with excess blasts in transformation) OR International Prognostic Scoring System MDS prognostic score > 1.5 - Not a candidate for allogenic bone marrow transplantation* from a related sibling donor (i.e., HLA-identical sibling) - No known standard or potentially curative therapy exists or is capable of extending life expectancy - No clinical symptoms suggesting CNS leukemia - Performance status - ECOG 0-2 - At least 60 days - See Disease Characteristics - Bilirubin = 1.5 times upper limit of normal (unless attributed to underlying disease) - Creatinine clearance = 60 mL/min - No New York Heart Association class III-IV heart failure - No myocardial infarction within the past year - LVEF = 40% by MUGA - No cardiac symptoms = grade 2 - No uncontrolled dysrhythmia requiring medication - No poorly controlled angina - QTc = 450 msec for men and = 470 msec for women - No congenital long QT syndrome - No left bundle branch block - No ischemic heart disease within the past 6 months - No history of cardiac toxicity after treatment with anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine - No other significant cardiac disease - No active uncontrolled infection - No history of serious allergic reaction to eggs - No known HIV infection or AIDS (with or without highly active antiretroviral treatment) - DLCO > 80% - No pulmonary symptoms = grade 2 - No symptomatic pulmonary disease requiring medication including any of the following: - Dyspnea on or off exertion - Paroxysmal nocturnal dyspnea - Significant pulmonary disease (e.g., chronic obstruction/restrictive pulmonary disease) - No oxygen requirement - No home oxygen that meets the medicare requirement - No history of pulmonary toxicity after treatment with anthracyclines (e.g., doxorubicin hydrochloride, daunorubicin hydrochloride, mitoxantrone hydrochloride, bleomycin, or carmustine - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No psychosis - No other serious underlying medical condition that would preclude study participation - No prior allogeneic or autologous bone marrow transplantation - No concurrent immunotherapy - No concurrent biologic agents - No concurrent gene therapy - See Disease Characteristics - Recovered from prior chemotherapy - At least 48 hours since prior hydroxyurea for prevention of leukostasis - No other concurrent chemotherapy - At least 48 hours since prior glucocorticoids for prevention of leukostasis - No prior radiotherapy that included the heart in the field (e.g., mantle) or chest - No concurrent radiotherapy - No concurrent drugs that may cause QTc prolongation - No concurrent participation in another clinical trial involving a pharmacologic agent for symptom control or therapeutic intent - No other concurrent investigational drugs or therapy |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tolerability of tanespimycin with cytarabine in patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, or high-grade myelodysplastic syndromes | Evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 standard toxicity grading. | Day 21 | Yes |
Secondary | Clinical response | Evaluated as suggested by the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Summarized by simple descriptive summary statistics across all patients in each group as well as by dose level. Possible relationships between response and dose level will be explored graphically. | Every 2 weeks | No |
Secondary | Plasma level of tanespimycin | Summarized by simple descriptive summary statistics across all patients in each group as well as by dose level. Possible relationships between pharmacokinetic (PK) parameters and p450 3A5 genotypes will be explored. | Day 3 | No |
Secondary | Effects on client proteins | Analyzed by immunoblotting. Results will be displayed graphically and analyzed using simple descriptive statistics. | Days 1, 3, and 4 of course 1 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT06159491 -
Pacritinib in CMML
|
Phase 1/Phase 2 | |
Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
Recruiting |
NCT01133886 -
Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure
|
Phase 2 | |
Completed |
NCT01169012 -
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
|
Phase 1 | |
Completed |
NCT01233921 -
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
N/A | |
Terminated |
NCT00509249 -
Aflibercept in Treating Patients With Myelodysplastic Syndromes
|
Phase 2 | |
Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
Completed |
NCT00096122 -
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT00171912 -
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
|
Phase 2 | |
Completed |
NCT00078858 -
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
|
Phase 1/Phase 2 | |
Completed |
NCT00052520 -
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT03683433 -
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
|
Phase 2 | |
Recruiting |
NCT04980404 -
Inqovi Maintenance Therapy in Myeloid Neoplasms
|
Phase 1 | |
Active, not recruiting |
NCT03588078 -
Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
|
Phase 1/Phase 2 | |
Withdrawn |
NCT06085638 -
Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT03999723 -
Combining Active and Passive DNA Hypomethylation
|
Phase 2 | |
Terminated |
NCT00852709 -
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
|
Phase 1 |